Protective Effect of Propolis on Doxorubicin Induced Cardio- and Nephrotoxicity

Samaa Yassin Ali; Adel Abdel-moneim; Eman Salah Abdel-Reheim*

Molecular Physiology Division, Zoology Department, Faculty of Science, Beni-Seuf University, Beni-Seuf, Egypt.

Abstract

Doxorubicin, is an antineoplastic drug, induces objective tumor responses in solid tumors as well as in hematologic malignancies. Its major adverse effect are cardiotoxicity and nephrotoxicity. Bee products, such as honey, royal jelly, pollen, and propolis have great attention in recent years. Propolis contains a broad spectrum of compounds that have many biological activities. Cardiotoxicity as well as nephrotoxicity was induced in rats by intraperitoneal injection of doxorubicin (10 mg/kg) and protected or treated by (200 mg/kg/ day) of propolis extract administrated by gastric intubation for four weeks before or after doxorubicin administration. Cardiac biomarkers such as BNP, troponin T, LDH, CK, and AST in addition to creatinine and urea measurements, all ameliorated in the propolis; protected or treated groups. Cardiac and renal oxidative stress indicated by increased MDA and decreased antioxidant enzymes such as catalase, GSH and SOD in doxorubicin administrated group. This cardiac oxidation was improved in the other propolis pre- or post-treated groups. The measured lipid profile was also ameliorated with increased HDL in propolis groups. The study investigates that propolis has a protective and treatment effects against doxorubicin induced cardiotoxicity and nephrotoxicity mainly by its powerful antioxidant and lipid lowering efficacy.

Keywords: Propolis; Doxorubicin; Cardiotoxicity; Nephrotoxicity; BNP; Troponin T.

Introduction

Doxorubicin (DOX) also known as Adriamycin it is an anthracyclin antineoplastic antibody was isolated in the early 1960s from the pigment-producing bacterium Streptomyces peucetius var. caesius [1]. Intercalation of DOX with a DNA molecule is recognized as the basic mechanism of its effect. Doxorubicin binds directly to DNA via intercalation between base pairs on the DNA helix. Doxorubicin also inhibits DNA repair by inhibiting topoisomerase II. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA [2]. Doxorubicin is a powerful iron-chelator. The iron-doxorubicin complex can bind DNA and cell membranes producing free radicals that immediately cleave DNA and cell membranes. Although maximally cytotoxic in S phase, doxorubicin is not cell cycle-specific [3]. DOX was clinically used to treat a variety of cancers including breast, ovarian, and lymphoma [4]. Although doxorubicin remains one of the most important anticancer drugs in the clinic,
unfortunately, its potent antitumor activity is also accompanied by sever tissue toxicities such as cardiotoxicity [4].

In 1991, long-term cardiotoxic effects were identified in patients with acute lymphoid leukemia in childhood [5]. Patients with childhood cancer and those treated with DOX have a high risk of developing symptomatic cardiac events at an early stage, and this risk remains high within 30 years after treatment. In addition, it is estimated that one in eight DOX-treated patients will be affected with severe cardiac disease [6].

Cardiotoxicity is defined as toxicity that affects the heart by the US National cancer institute. Although simple to understand in theory, this definition is very broad and in the case of cancer treatments, may encompass many effects, such as cardiac dysfunction and heart failure, myocardial ischemia or infarction, valvular abnormalities, pericardial disease, hypertension, and arrhythmias [7].

The exact mechanism of anthracyclin induced cardiotoxicity remains unclear, though it is likely to be multifactorial with different potential pathways involved that leads to cardiomyocyte death [6,8,9]. Until now, the main mechanisms that have been proposed by various research groups include oxidative stress, iron metabolism, Ca²⁺ hemostasis dysregulation, sarcomere structure alterations, gene expression modulation and apoptosis [8-11]. Since several mechanisms are involved in the development of cardiac toxicity, different strategies are being performed to prevent DOX-induced cardiomyopathy.

Renal dysfunction is among the noticeable negative effects of nephrotoxicity induced by doxorubicin increased permeability of the capillary of the glomerulus and tubular atrophy occur in the renal tissue of rats during DOX induction [12]. The toxicity of DOX on kidneys hasn’t been clarified yet it may be due to imbalanced oxidant-antioxidant systems, free radical formation, iron-dependent oxidative damage of biological macromolecules, membrane lipid peroxidation (LPO), and protein oxidation. The disturbance in oxidant-antioxidant systems, which has been demonstrated with LPO and protein oxidation, results in tissue injury [13].

Propolis or bee glue, is a dark-colored resinous substance collected by honeybees from leaf buds and cracks in the bark of various tree species [14]. Propolis has been used as a folk medicine since 300 BC [15]. Recently, numerous biological properties of propolis have been reported including antibacterial, antifungal, antiviral, immunoregulatory, anti-oxidative, anti-tumor, hepatoprotective and anti-inflammatory [14]. Because of the wide range of biological activities, propolis has recently been extensively used in food and beverages to improve health and prevent diseases [15]. The chemical composition of propolis is quite complicated and over 300 components have been identified including flavonoids, phenolic acids, esters, terpenoids, steroids and amino acids [16]. The data administrated in this search study the protective or treatment effect of propolis against cardioto-and nephrotoxicity induced by doxorubicin.

Materials and methods

Animals

A total of 32 male albino Wistar rats (Rattus norvegicus) weighing (110-130 g) were obtained from the Animal Farm of the Egyptian Holding Company for Biological Products and Vaccines, Cairo, Egypt. Animals were housed in plastic cages and maintained under standard conditions of temperature, humidity and 12 h light/dark cycle along the experimental period. Rats were provided with a pellet of concentrated diet containing all the necessary nutritive elements. Rats were left to acclimatize for 1 week before starting the experiment. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC), Beni-Suef University, Egypt (BSU/FS/2015/11).

Chemicals

Doxorubicin hydrochlorid (10 mg vial for injection) is the active ingredient of Adriamiblastina. It is produced from Pharmacie Company and purchased from local pharmacy.

Preparation of extract

Crude propolis was obtained from faculty of agriculture, Fayoum University and was prepared according to the method of Mani [17].

Experimental designs

The rats were divided equally into 4 groups (each group contains 8 rats) as following:

Group I (normal control): rats were kept under the standard condition for four weeks then scarified at the end of the experiment.

Group II (doxorubicin): It is the positive control group; rats were injected once with intraperitoneal doxorubicin (10 mg/kg) [4] then sacrificed after 48 hours.

Group III (propolis+ doxorubicin): It is the protected group, rats were received propolis (200 mg/kg) [14] daily for four weeks by gastric intubation then injected with intraperitoneal doxorubicin (10 mg/kg) and sacrificed after 48 hours.

Group IV (doxorubicin+ propolis): It is the treated group, rats were injected with intraperitoneal doxorubicin (10 mg/kg) then after 2 days, started to receive propolis (200 mg/kg) daily for four weeks and sacrificed at the end.

At the end of experiment, overnight fasted rats were sacrificed under light diethyl ether anesthesia. The blood samples were collected and serum was obtained after centrifugation of blood samples at 3000 rpm for 10 minutes. Heart and kidney were directly separated after scarification, washed in ice-cold saline then was homogenized in saline (10% W/V) and the homogenates were stored at -30°C until oxidation parameters were assayed.

Biochemical measurements

Creatinine kinase (CK) and lactate dehydrogenase (LDH) were determined kinetically using reagent kits purchased from Spectrum Company (Egypt). Glutamic oxaloacetate transaminase (GOT) and Creatinine concentration were determined kinetically using reagent kits purchased from Bioscope Diagnostics Chemical Company (Egypt). Troponin T was determined using an enzyme-linked immunosorbent assay (ELISA) by the method of Bhaskar and Rao [18]. Brain natriuretic peptide (BNP) was determined by the method of Bibbins-Domingo et al. [19]. Urea concentration was determined enzymatically colorimetric using kits purchased from Diamond Diagnostics Chemical Company (Germany). Cholesterol, triglycerides and high density lipoprotein (HDL) cholesterol were measured by colorimetric reagent kits purchased from Spinreact Company (Spain). Low density lipoprotein (LDL) and very low density lipoprotein (vLDL) chole-
terol concentration were determined according to Friedewald et al. and Norbert reactions respectively:

\[
LDL\text{-cholesterol}= \text{Total cholesterol} - \text{Triglycerides} / 5 - \text{HDL-cholesterol}
\]

\[
vLDL\text{-cholesterol}= \text{Triglycerides} / 5
\]

Heart and kidney homogenates were used to assay oxidation state of the organs. Malondialdehyde (MDA) (lipid peroxidation marker) was determined by the method of Preuss et al. Catalase (CAT) and superoxide dismutase (SOD) activities were determined by the methods of Cohen et al. and Kakkar et al. respectively. Glutathione (GT) content was determined by the method of Beutler et al.

**Statistical analysis**

The data were analyzed using oneway ANOVA followed by Tukey-Kramer method for post-hoc analysis to compare various groups with each other. The results were expressed as mean ± standard error (SE). Statistical significance interval is considered as P < 0.05 for all data. All results were analyzed using Statistical Package for Social Science (SPSS) version 20 software.

**Results**

Administration of doxorubicin induced cardiac toxicity. The cardiac biomarkers such as CK, LDH, GOT were significantly elevated in doxorubicin group in comparison with normal group while in groups administrated propolis before or after doxorubicin administration showed a significant decrease (P<0.001) compared to doxorubicin group (Table 1). Troponin T, BNP were significantly (P<0.001) elevated in doxorubicin group in comparison with normal group while in groups administrated propolis before or after doxorubicin administration show significant decrease (P<0.001) compared to doxorubicin group (Figure 1). Table 2 showed that propolis ameliorate the levels of lipid profile in the groups of rats administrated it before or after doxorubicin. Table 3 showed that doxorubicin administration produced oxidative stress in cardiac tissue as indicated by increased MDA (P<0.001) while cardiac CAT, SOD and GSH were decreased significantly in comparison with normal control rats. These were ameliorated totally in propolis protected or treated groups. Kidney function measured by creatinine and urea was designated in Figure 2 while table 4 indicated the toxic effect of doxorubicin in the renal oxidation. This was presented by significant elevated MDA and decreased antioxidant enzyme activities, improved by propolis. On the other hand, GSH was not significantly changed in the all groups.
### Table 1: The effect of propolis on cardiac enzyme doxorubicin administrated rats.

<table>
<thead>
<tr>
<th>Parameters/Groups</th>
<th>CK (U/L)</th>
<th>LD (U/L)</th>
<th>AST (U/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control</td>
<td>315.67 ± 34.21†</td>
<td>547.67± 71.002</td>
<td>68.00 ± 6.36†</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>738.00± 55.26ab</td>
<td>1917.00± 33.025c</td>
<td>123.00 ± 6.11b</td>
</tr>
<tr>
<td>Propolis + Doxorubicin</td>
<td>254.00±23.04ab</td>
<td>1473.50± 103.067a</td>
<td>83.17 ± 3.53†</td>
</tr>
<tr>
<td>Doxorubicin + Propolis</td>
<td>207.67±74.36a</td>
<td>1436.83± 115.574a</td>
<td>65.83 ± 5.46a</td>
</tr>
<tr>
<td>F-Probability</td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
</tr>
</tbody>
</table>

*Data are expressed as mean ± standard error. Number of animals in each group is Six.
*Means, which have the same superscript symbol(s), are not significantly different.
P-value < 0.05 is significant.

### Table 2: The effect of propolis on serum lipid profile in doxorubicin administrated rats.

<table>
<thead>
<tr>
<th>Parameters/Groups</th>
<th>Cholesterol (mg/dl)</th>
<th>Triglycerides (mg/dl)</th>
<th>HDL (mg/dl)</th>
<th>LDL (mg/dl)</th>
<th>vLDL (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control</td>
<td>55.8 ± 1.4a</td>
<td>89± 2.8b</td>
<td>70 ± 1.9b</td>
<td>32± 2.0a</td>
<td>18± 0.6a</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>131.00± 6.9a</td>
<td>189± 1.6a</td>
<td>44 ± 3.4a</td>
<td>57± 9.5a</td>
<td>38 ± 0.33c</td>
</tr>
<tr>
<td>Propolis + Doxorubicin</td>
<td>44.17± 1.5a</td>
<td>72± 1.8c</td>
<td>75 ± 2.2c</td>
<td>44 ± 2.8c</td>
<td>14 ± 0.31c</td>
</tr>
<tr>
<td>Doxorubicin + Propolis</td>
<td>51.5±1.7a</td>
<td>76± 2.7a</td>
<td>70 ± 1.0b</td>
<td>33 ± 1.9b</td>
<td>15 ± 0.55a</td>
</tr>
<tr>
<td>F-Probability</td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
<td>P&lt;0.01</td>
<td>P&lt;0.001</td>
</tr>
</tbody>
</table>

*Data are expressed as mean ± standard error. Number of animals in each group is Six.
*Means, which have the same superscript symbol(s), are not significantly different.
P-value < 0.05 is significant.

### Table 3: The effect of propolis on the cardiac oxidation of doxorubicin administrated rats.

<table>
<thead>
<tr>
<th>Parameters/Groups</th>
<th>Cardiac MDA (nmole/gm)</th>
<th>Cardiac CAT (k*100)</th>
<th>Cardiac SOD (U/g )</th>
<th>Cardiac GSH (nmol/g )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control</td>
<td>147 ± 8.65 a</td>
<td>16.9 ± 0.87 a</td>
<td>98.50 ± 7.71a</td>
<td>72.83 ± 1.85 a</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>180 ± 3.22 b</td>
<td>12.1 ± 0.298 a</td>
<td>66.83 ± 5.02a</td>
<td>55.33 ± 2.26 a</td>
</tr>
<tr>
<td>Propolis + Doxorubicin</td>
<td>133 ± 9.03 c</td>
<td>14.9 ± 1.083 ab</td>
<td>99.17 ± 8.91a</td>
<td>65.08 ± 1.87 ab</td>
</tr>
<tr>
<td>Doxorubicin + Propolis</td>
<td>130 ± 7.63 c</td>
<td>14.4 ± 0.545 ab</td>
<td>81.67 ± 1.91ab</td>
<td>73.52 ± 4.07 b</td>
</tr>
<tr>
<td>F-Probability</td>
<td>P&lt;0.001</td>
<td>P&lt;0.01</td>
<td>P&lt;0.01</td>
<td>P&lt;0.001</td>
</tr>
</tbody>
</table>

*Data are expressed as mean ± standard error. Number of animals in each group is Six.
*Means, which have the same superscript symbol(s), are not significantly different.
P-value < 0.05 is significant.

### Table 4: The effect of propolis on the renal oxidation of doxorubicin.

<table>
<thead>
<tr>
<th>Parameters/Groups</th>
<th>Renal MDA (nmole/gm)</th>
<th>Renal CAT (k*100)</th>
<th>Renal SOD (U/g )</th>
<th>Renal GSH (nmol/g )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control</td>
<td>123 ± 15.20 ab</td>
<td>37.83 ± 1.74 a</td>
<td>68.53 ± 2.01b</td>
<td>76.00 ± 3.48a</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>173 ± 2.76 c</td>
<td>28.67 ± 0.69 a</td>
<td>40.50 ± 1.93a</td>
<td>64.33 ± 1.45 a</td>
</tr>
<tr>
<td>Propolis + Doxorubicin</td>
<td>113 ± 13.00 c</td>
<td>37.55 ± 1.76b</td>
<td>69.00 ± 2.24b</td>
<td>75.25 ± 2.12 b</td>
</tr>
<tr>
<td>Doxorubicin + Propolis</td>
<td>159 ± 8.33 ab</td>
<td>36.18 ± 1.76b</td>
<td>67.50 ± 1.61b</td>
<td>71.00 ± 4.07 b</td>
</tr>
<tr>
<td>F-Probability</td>
<td>P&lt;0.01</td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
<td>P&lt;0.05</td>
</tr>
</tbody>
</table>

*Data are expressed as mean ± standard error. Number of animals in each group is Six.
*Means, which have the same superscript symbol(s), are not significantly different.
P-value < 0.05 is significant.
Discussion

Doxorubicin is a DNA topoisomerase II (Top2) targeted therapy [20]. The antitumor activity of doxorubicin is mediated by poisoning of Top2 (primarily the Top2α isozyme) and formation of Top2α-DNA covalent adducts. Doxorubicin mediated redox cycling and therefore ROS generation [21]. Unbalanced production and degradation of ROS and RNS can result in accumulation of these reactive species, commonly referred to as oxidative stress. ROS are usually detoxified by intracellular enzymes, such as glutathione reductase, superoxide dismutase, and catalase [22]. Exposure of macromolecules (lipid, proteins, DNA, etc.) to reactive species results in oxidative modifications with deleterious effects [23,24]. Administration of doxorubicin decrease antioxidant enzymes activity [25] and decreased levels of cardiac glutathione or superoxide dismutase and catalase activities. The myocardium injury evidenced by lipid peroxidation occurs as a result of the increase of the reactive oxygen species (ROS) production, including superoxide (O$_2^-$) and hydroxyl radicals (OH$^-$) as well as other non-radicals such as hydrogen peroxide (H$_2$O$_2$), singlet oxygen (O$_2$), etc. [1,6,11]. Excessive production of free radicals damages the myocardium which leads to increased membrane permeability and leads to the increase of LDH, CK and AST concentration in serum [26].

The mechanism of doxorubicin induced cardiotoxicity include oxidative stress, iron metabolism, Ca$^{2+}$ homeostasis dysregulation, sarcomere structure alterations, gene expression modulation, and apoptosis [9,10]. Doxorubicin induced diastolic dysfunction related to other pathologies. Increased oxidative stress and intracellular Ca$^{2+}$ dysregulation is commonly present and closely interconnected [8,11].

Troponins are myocardial regulatory proteins, which regulate the calcium mediated actin and myosin interaction. Troponin-T is widely used as specific marker to diagnose myocardial infarction [27]. In this study propolis minimized the elevated effect of doxorubicin on troponin T when it administrated before or after doxorubicin. The release of BNP reflects the alterations in left ventricular potency as a response to B-adrenergic stimulation on the heart. These effects are mediated through B-1 and B-2 adrenoceptors, mediating the positive inotropic and chrono- 

The significant increase in BNP level in doxorubicin group may be related to nephrotoxic as well as cardiotoxic effects of doxorubicin. Renal failure may result in increased concentrations of BNP as the cardiac ventricles rapidly release BNP paired with NT-proBNP to increase vasodilation and renal output of sodium and water to counter the increased fluid volume resulting from decreased renal function [39].

References


